Genfit Sa · EURONEXT:GNFT
Genfit Sa — Investor Presentation (December 2024)
110 slides from Genfit Sa's investor presentation, December 2024
Slide 1: Corporate presentation December 2024
Corporate presentation DECEMBER, 2024
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED B
Slide 3: Towards a new GENFIT
Towards a new GENFIT ACLF disease state GENFIT’s approach to ACLF ACLF market opportunity Highlights on newsflow
Slide 4: GENFIT Highlights
GENFIT Highlights VS-01 (UNVEIL-IT® - Phase 2) 5 assets in ACLF & VS-01 (Proof of Concept) its complications NTZ (Proof of Concept) French biopharmaceutical company SRT-015 (First-in-Human Study*) Dual-listed on EURONEXT & NASDAQ (GNFT) CLM-022 (preclinical) VS-02-HE (preclinical) Improving the life
Slide 5: Towards a new GENFIT
Towards a new GENFIT Strategic Shift Inception Clinical development Focus on rare and life-threatening liver & early years in chronic liver diseases diseases with high unmet needs 1999 2024 A diversified pipeline in ACLF (6 programs) and Development of Research Development of elafibranor in MASH oth
Slide 6: The elafibranor story in PBC
The elafibranor story in PBC Start of Phase 1 clinical elafibranor accepted as Exclusive licensing trials for GFT505 the generic name for agreement with Ipsen GFT505 by the WHO 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Filing 1st PC
Slide 7: Pipeline
Pipeline Commercial stage ▪ Approval U.S. FDA June 10, 2024 Iqirvo® (elafibranor1,8) in PBC ▪ Approval EMA September 19, 2024 ▪ Approval CHMRA UK October 8, 2024 Research and Clinical Development stage – Data Readout from 5 Clinical Trials 2H25 Preclinical Phase 1 Phase 2 Phase 3 Next expected/targe
Slide 8: ACLF Disease state – PART I
Towards a new GENFIT ACLF Disease state – PART I P r . R . M o re a u , M D, S e n i o r S c i e n t i s t ( O u t s t a n d i n g G ra d e ) , I N S E R M GENFIT’s approach to ACLF ACLF market opportunity Highlights on newsflow
Slide 9: Professeur Richard Moreau, Founding Member of EF-CLIF
Professeur Richard Moreau, Founding Member of EF-CLIF and Worldwide Leader in ACLF 9
Slide 10: Acute-on-Chronic Liver Failure (ACLF)
ACLF Day December 12, 2023 Acute-on-Chronic Liver Failure (ACLF) Richard Moreau, MD, FAASLD,1,2,3 1European Foundation for the Study of Chronic Liver Failure (EF CLIF), Barcelona, Spain; 2Centre de Recherche sur l’Inflammation (CRI), INSERM, Université Paris Cité, CNRS, Paris, France; 3Service d’hép
Slide 11: Outline
Outline • Cirrhosis & ACLF • Defining ACLF • Pathophysiology • Medical management • Liver transplantation • Unmet needs
Slide 12: Cirrhosis
•. Cirrhosis • 11th most common cause of death o 2 million deaths worldwide/year (~4% of deaths worldwide) • 2 billion consume alcohol o At risk for alcohol-associated cirrhosis • 2 billion overweight/obese o At risk for metabolic-associated cirrhosis Asrani et al. J Hepatol 2019;70:151-71. Devarbha
Slide 13: Characteristics of Cirrhosis
Characteristics of Cirrhosis • Chronic liver disease • Compensated for years • Decompensated: ascites, gastrointestinal hemorrhage, hepatic encephalopathy o Recent onset defines acute decompensation • Acute decompensation: often leads to nonelective hospital admission • ACLF: cause of death in acute
Slide 14: Characteristics of ACLF
Characteristics of ACLF • Men ~55 yr • Seen among patients nonelectively admitted for acutely decompensated cirrhosis • Defined by impaired function of major organ systems & intense systemic inflammation • Associated with high short-term mortality (by 28 & 90 days) • Engages health-care system resou
Slide 15: ACLF Burden in Europe
ACLF Burden in Europe • Under evaluation (commissioned by Journal of Hepatology) • Currently estimated to ~150,000 cases/yr (projection from German data).
Slide 16: Evidence-Based Knowledge Produced by EF CLIF
Evidence-Based Knowledge Produced by EF CLIF • Studies in patients nonelectively admitted for acute decompensation: o CANONIC: 1343 European patients o PREDICT: 1273 European patients o ACLARA: 1274 LATAM patients Moreau et al. Gastroenterology 2013;144:1426-37. Trebicka et al. J Hepatol 2020;73:842
Slide 17: Outline
Outline • Cirrhosis & ACLF • Defining ACLF • Pathophysiology • Medical management • Liver transplantation • Unmet needs
Slide 18: Diagnostic Criteria & Prevalence of Organ System Failures
Diagnostic Criteria & Prevalence of Organ System Failures (CANONIC Study) Prevalence Organ system Diagnostic criteria* (%) Liver Bilirubin ≥12 mg/dL 15.4 Kidney Creatinine ≥2 mg/dL or 12.6 RRT Coagulation INR ≥2.5 7.8 Brain Grade 3 or 4 HE 7.4 Circulation Use of vasopressor 4.8 Respiration SpO2/FiO2
Slide 19: The CANONIC Study Defined ACLF
The CANONIC Study Defined ACLF 1343 patients nonelectively admitted for acutely decompensated cirrhosis (new ascites, encephalopathy, infection, GI hemorrhage) 70% 30% Presence of ACLF Absence of ACLF • High-grade systemic inflammation • Low-grade systemic inflammation • Organ failures • No organ fa
Slide 20: Triggers of Inflammation & ACLF
Triggers of Inflammation & ACLF (PREDICT Study) Trigger Prevalence Type: Bacterial infection 44% Alcohol-related hepatitis 44% GI hemorrhage with shock 6% Toxic encephalopathy 6% Number: 1 46% ≥2 25% 0 29% Trebicka, Fernandez, et al. J Hepatol 2021:74;1097-108.
Slide 21: Clinical Course of ACLF Within the 1st Week
Clinical Course of ACLF Within st the 1 Week ACLF Grade at Day 7 Initial Grade 0 1 2 3 % patients ACLF-1 55 24 8 12 ACLF-2 35 15 25 25 ACLF-3 16 4 12 68 Gustot, Fernàndez, et al. Hepatology 2015;62:243-52.
Slide 22: 90-Day Transplantation-Free Survival According to Status at Day 7
90-Day Transplantation-Free Survival According to Status at Day 7 Among 329 Patients Had ACLF on Admission Arroyo, Moreau, Jalan. N Engl J Med 2020;382:2137-45.
Slide 23: ACLF is a Global Disorder
ACLF is a Global Disorder Europe USA Asia Latin America Arroyo, Moreau, Jalan. N Engl J Med 2020;382:2137-45.
Slide 24: Outline
Outline • Cirrhosis & ACLF • Defining ACLF • Pathophysiology • Medical management • Liver transplantation • Unmet needs
Slide 25: Inducers of Inflammation
Inducers of Inflammation • Pathogen-associated molecular patterns (PAMPs) = bacterial byproducts immediately recognized by immune system; induce inflammation • Damage-associated molecular patterns (DAMPs) = intracellular molecules released by dying cells; immediately recognized by immune system; ind
Slide 26: Inducers of Inflammation According to Triggers
Inducers of Inflammation According to Triggers Liver injury Infection (cell death) No apparent trigger PAMPs DAMPs PAMPs Systemic inflammation Organ failures Arroyo, Moreau, Jalan. N Engl J Med 2020;382:2137-45.
Slide 27: Impaired Gut Barrier in Decompensated Cirrhosis
Impaired Gut Barrier in Decompensated Cirrhosis • Changes in gut microbiome (↑ pathobionts = “bad” bacteria) • ↑ Intestinal permeability to bacteria and/or bacterial PAMPs • Translocation of bacteria and/or bacterial PAMPs to blood flowing to the liver • ↓ Function of the “hepatic filter”; bacteria
Slide 28: Outline
Outline • Cirrhosis & ACLF • Defining ACLF • Pathophysiology • Medical management • Liver transplantation • Unmet needs
Slide 29: Key Points
Key Points • Main principle: Diagnose acute precipitants & treat them urgently • Provide supportive therapy in ICU • Objective: Bridge to early liver transplantation • No “pathophysiology-based” therapy available. Arroyo, Moreau, Jalan. N Engl J Med 2020;382:2137-45. EASL CPG. J Hepatol 2023;79:461-
Slide 30: Supportive Therapy
Supportive Therapy • Cardiovascular: vasoconstrictors. • Respiratory: mechanical ventilation. • Brain: protective intubation if necessary; lactulose; albumin dialysis (MARS) if lactulose failure. • Liver: 2 negative RCTs of extracorporeal MARS. Arroyo, Moreau, Jalan. N Engl J Med 2020;382:2137-45. E
Slide 31: Other Interventions
Other Interventions • Granulocyte colony-stimulating factor o No efficacy • Plasma exchange o Trial recruiting • Cell therapy o Under evaluation EASL CPG. J Hepatol 2023;79:461-91.
Slide 32: Outline
Outline • Cirrhosis & ACLF • Defining ACLF • Pathophysiology • Medical management • Liver transplantation • Unmet needs
Slide 33: Survival Among Patients with ACLF-2, -3 With or Without Early Transplant
Survival Among Patients with ACLF-2, -3 who Did or Did not Receive Early (<28 days) Liver Transplant Gustot, Fernandez, et al. Hepatology 2015;62:243-52.
Slide 34: Narrow window for liver transplantation
Survival Among Patients with ACLF-2, -3 who Did or Did not Receive Early (<28 days) Liver Transplant Narrow window for liver transplantation Gustot, Fernandez, et al. Hepatology 2015;62:243-52.
Slide 35: Liver Transplantation in Patients with ACLF
Liver Transplantation in Patients with ACLF ACLF-3 only Artru et al. J Hepatol 2017; 67:708-15.
Slide 36: Outline
Outline • Cirrhosis & ACLF • Defining ACLF • Pathophysiology • Medical management • Liver transplantation • Unmet needs
Slide 37: Targeting Bacterial/PAMP Translocation
Targeting Bacterial/PAMP Translocation • Current approaches are based on antibiotics • Restricted to few patients • Major issues with antibiotic use (emergence of multidrug-resistant bacteria) • Alternative approaches: unmet need.
Slide 38: Conclusions
Conclusions • ACLF is the most severe form of acutely decompensated cirrhosis • Bacterial/PAMP translocation & systemic inflammation are key pathogenic mechanisms • There is no “pathophysiology-based” therapy currently available • Liver transplantation is effective but limited due to narrow time, or
Slide 39: ACLF Disease state – PART II
Towards a new GENFIT ACLF Disease state – PART II D r . J e n n i f e r L a i ( U C S F ) , M D, M BA GENFIT’s approach to ACLF ACLF market opportunity Highlights on newsflow
Slide 40: Acute-on-Chronic Liver Failure (ACLF)
Acute-on-Chronic Liver Failure (ACLF) Jennifer C. Lai, MD, MBA Transplant Hepatologist Endowed Professor of Liver Health & Transplantation University of California, San Francisco (UCSF)
Slide 41: Acute-on-Chronic Liver Failure: Defined
Acute-on-Chronic Liver Failure : Defined …a potentially reversible condition in patients with chronic liver disease with or without cirrhosis that is associated with potential for multiple organ failure and high mortality within 3 months in the absence of treatment… Bajaj J, et al. Am J Gastro 2022.
Slide 42: There is no direct therapeutic for ACLF
“ There is no direct therapeutic for ACLF.
Slide 43: Scope of the underlying problem
SCOPE OF THE UNDERLYING PROBLEM : Chronic liver disease & cirrhosis
Slide 44: Chronic Liver Disease & Cirrhosis
Chronic Liver Disease & Cirrhosis 11th most common cause of death 2 million deaths worldwide (~4% of deaths worldwide) 2 billion consume alcohol At risk for alcohol-associated liver disease / cirrhosis 2 billion overweight/obese At risk for non-alcoholic fatty liver disease / cirrhosis Asrani S, et
Slide 45: Deaths by liver disease etiology: Rising
Deaths by liver disease etiology : RISING Other NASH HCV HBV Alcohol Cheemerla S, et al. Clin Liv Dis 2021. https://vizhub.healthdata.org/gbd-results/
Slide 46: Economic burden of chronic conditions in the U.S.
Economic burden of chronic conditions in the U.S. : Cirrhosis and ACLF much higher! Chronic Length of Inpatient Mean cost per disease hospital stay mortality hospitalization Pneumonia 5 days 3.3% $7,581 Congestive heart 5 days 3.0% $8,315 failure Cerebrovascular 6 days 4.7% $8,117 disease Cirrhosis
Slide 47: The Patient: Clinical Course & Features
THE PATIENT : Clinical Course & Features
Slide 48: Trajectories of liver function in common liver states
Trajectories of liver function in 3 common liver states Mahmud N, et al. Curr Hep Reports 2020.
Slide 49: Trajectories of liver function in common liver states
Trajectories of liver function in 3 common liver states Mahmud N, et al. Curr Hep Reports 2020.
Slide 50: Trajectories of liver function in common liver states
Trajectories of liver function in 3 common liver states Mahmud N, et al. Curr Hep Reports 2020.
Slide 51: Trajectories of liver function in common liver states
Trajectories of liver function in 3 common liver states Mahmud N, et al. Curr Hep Reports 2020.
Slide 52: Clinical characteristics (U.S. cohort)
Clinical characteristics (U.S. cohort) Reason for n=1,031 admission n=1,031 Age (years) 57 (11) Bacterial infection 25% Men 66% GI bleed 16% Liver disease etiology Hepatic enceph. 17% Alcohol only 31% Renal dysfxn 12% HCV only 21% Alcohol related 4% Alcohol + HCV 15% Electrolytes abnl 3% NASH 17% Ot
Slide 53: Role of prior hepatic decompensation
Role of prior hepatic decompensation n=417 No prior event 26% <3 months prior 16% 3-12 prior 17% >12 months prior 41% Moreau R, et al. Gastroenterol 2013.
Slide 54: Percent with extra-hepatic organ failure on admission
Percent with extra-hepatic organ failure on admission RENAL NEUROLOGIC CIRCULATORY RESPIRATORY 50% 22% 23% 13% Arroyo V, et al. J Hepatol 2015.
Slide 55: ACLF Scoring System
ACLF Scoring System Chronic Liver Failure Consortium (CLIF-C) ACLF CLIF-C ACLF Organ No ACLF Total bilirubin Liver PT-INR Kidney Creatinine ACLF-1 Hepatic Brain encephalopathy ACLF-2 Circulatory Blood pressure Respiratory Oxygenation ACLF-3 *CLIF-C ACLF = 10 x [0.33 x CLIF-Organ Failures + 0.04 x Ag
Slide 56: Probability of survival by ACLF severity
Probability of survival by ACLF severity Increasing # / severity The greater the number/severity of organ failures, the greater the risk of death. Gustot T, et al. Hepatol 2015. Arroyo V, et al. NEJM 2020.
Slide 57: Pathogenesis: Leading hypotheses and supporting data
PATHOGENESIS : Leading hypotheses and supporting data
Slide 58: Portal hypertension
The underlying condition ➢ Circulatory system at maximum capacity Portal ➢ Impaired gut circulation → altered gut microbiome → impaired gut mucosal hypertension defense system 101 Simonetto DA, et al. Mayo Arroyo V, et al. JClinic Proc Hepatol 2019. 2014.
Slide 59: Greater severity of liver disease is associated with less diverse microbiome
Greater severity of liver disease is associated with less diverse microbiome Is there a role for gut microbiota manipulation to improve ACLF outcomes? Sole C, et al. Gastroenterol 2021.
Slide 60: Portal hypertension
The underlying condition ➢ Circulatory system at maximum capacity ➢ Impaired gut circulation → altered gut Portal microbiome → impaired gut mucosal defense system hypertension 101 ➢ Increased intestinal permeability → chronic bacterial translocation ➢ Chronic systemic inflammation Simonetto DA, et a
Slide 61: Systemic inflammation hypothesis of ACLF
The acute insult Acute precipitant Exacerbation Acute on chronic of portal systemic hypertension inflammation Systemic inflammation hypothesis of ACLF Arroyo V, et al. J Hep 2021. Fig adapted Arroyo V, et al.from Arroyo J Hepatol V, et al. J Hepatol 2014. 2014.
Slide 62: Systemic inflammatory markers and risk of ACLF
Systemic inflammatory markers and risk of ACLF Escalating risk as systemic inflammatory markers increase Kimman M, Trebicka J. J Pers Med 2023. Arroyo V, et al. J Hep 2021.
Slide 63: Systemic inflammatory markers are elevated
Systemic inflammatory markers are elevated Is there a role for targeting systemic inflammation to improve ACLF outcomes? Trebicka J, et al. Front Immunol 2019.
Slide 64: At the Bedside: Management
AT THE BEDSIDE : Management
Slide 65: There is no direct therapeutic for ACLF
“ There is no direct therapeutic for ACLF.
Slide 66: Portal hypertension and systemic inflammation
Portal hypertension Systemic inflammation - Circulatory system is maximally - accommodating (little room for more insult) - Splanchnic vasodilitation Bernal W, et al. J Hepatol 2021.
Slide 67: Goal of treatment: Buy time
GOAL OF TREATMENT : BUY TIME Allow the To allow To prepare precipitant families to for liver to resolve say goodbye transplant
Slide 68: Survival is better with transplant than without
Survival is better with transplant than without Gustot, et al. Hepatol 2015. Artru F, et al. J Hep 2017.
Slide 69: Transplant survival is acceptable in all ACLF grades
Transplant survival is acceptable in all ACLF grades Gustot, et al. Hepatol 2015. Artru F, et al. J Hep 2017.
Slide 70: Post-transplant healthcare utilization increases by stage of ACLF
Post-transplant healthcare utilization increases by stage of ACLF Sundaram V, et al. Clin Gastro Hep 2022.
Slide 71: Post-LT quality of life is significantly impaired
Post-LT quality of life is significantly impaired Sundaram V, et al. Clin Gastro Hep 2022.
Slide 72: Narrow window for liver transplantation
Narrow window for liver transplantation ACLF patient ~40% will recover ➢ ~4% of patients with cirrhosis are Too early listed for liver transplant ➢ 1 in 4 patients Transplant window listed for transplant die while waiting Too late Adapted from Mahmud N, et al. Curr Hep Reports 2020 and Gustot T, et
Slide 73: Interventions other than liver transplantation
Interventions other than liver transplantation : Statements from the ACG ACLF guidelines ◦ Artificial liver support systems “whether they provide any clinical benefit is unclear” ◦ Plasma exchange “its effect in ACLF is unknown” ◦ Granulocyte colony stimulating factor “we suggest against the use of
Slide 74: The Opportunity
The Opportunity - Systemic inflammation? ACLF patient - Microbiome? - Reinforce the gut brain barrier? Adapted from Mahmud N, et al. Curr Hep Reports 2020 and Gustot T, et al. J Hepatol 2018.
Slide 75: Key Points: ACLF (Disease state)
Key Points : ACLF (Disease state) ACLF is a highly lethal, resource-intensive condition that occurs in patients with chronic liver disease. Portal hypertension, altered microbiome, and systemic inflammation drive ACLF. There is no direct therapeutic for ACLF. - Liver transplantation, while effective
Slide 76: GENFIT's approach to ACLF
Towards a new GENFIT ACLF disease state GENFIT’s approach to ACLF ACLF market opportunity Highlights on newsflow
Slide 77: Building a targeted portfolio to address the unmet need in ACLF
Building a targeted portfolio to address the unmet need that exists with current (not approved) Standard of Care in ACLF Specific selection of strategic assets: based on pathophysiology1 of ACLF, as defined by liver experts and consortiums such as EF-CLIF (European Foundation for the study of Chroni
Slide 78: 5 assets with complementary mechanisms of action targeting key pathways
5 assets with complementary mechanisms of action targeting key pathways We are developing a diversified pipeline to better address the complexities of ACLF and improve treatment outcomes VS-01-ACLF NTZ SRT-015 CLM-022 VS-02-HE Peritoneal Oral Injectable Oral Liposomal-based Anti-inflammatory ASK1 NL
Slide 79: Patient Journey & Window of Opportunity for Treatment
Patient Journey & Window of Opportunity for Treatment VS-01 NTZ SRT-015 Multiorgan support in the VS-02 early course of ACLF CLM-022 TREATMENT GOALS - DYSBIOSIS - PAMPS - BACTERIAL TRANSLOCATION Recovery ▪ Resolve ACLF ▪ Improve survival ▪ Chance of liver transplant Transplantation (Tx) increased ▪
Slide 80: VS-01 Clinical Stage Program in ACLF
VS-01 Clinical Stage Program in ACLF
Slide 81: Extraction of Metabolites to Reduce Mortality
VS-01 Extraction of Metabolites to Reduce Mortality Standard of care VS-01 in brief Ascites drainage High unmet medical need in ACLF with no approved treatment and 112’000 cases1 Targets first-line treatment for VS-01 VS-01 scavenging liposomes ACLF to reverse the disease Delivered via in-place peri
Slide 82: First in Human Study
VS-01 First in Human Study Part A: Single Ascending Dose (n = 9) Part B: Multiple Doses (n = 3) Cohort 1 Cohort 2 Cohort 3 IDSMB Cohort 4 15 mL/kg 30 mL/kg 45 mL/kg 34-42 mL/kg daily for 4 days DETAILS OUTCOME • Study population (n=12): ✓ Generally safe and well tolerated - Decompensated liver cirrh
Slide 83: Phase 1b Preliminary Efficacy Results on Liver & Brain Function
VS-01 Phase 1b Preliminary Efficacy Results on Liver & Brain Function IMPACT ON OVERALL LIVER DOSE-DEPENDENT AMMONIA IMPROVEMENT IN DISEASE SEVERITY REMOVAL FROM THE BODY PSYCHOMETRIC TESTS FOR HE e.g., assessed by Child-Pugh Score (CPS) Ammonia clearance increased with VS-01 dosage in e.g., number
Slide 84: UNVEIL-IT Phase 2 Proof-of-Concept Trial
VS-01 UNVEIL-IT® Phase 2 Proof-of-Concept Trial Phase 2a Proof Of Concept Study of VS-01 in Patients with Acute-on-Chronic Liver Failure CLINICAL DATA READOUT OPEN-LABEL 1:1 RANDOMIZED CONTROLLED MULTI-CENTER GLOBAL STUDY TARGETED 2H2025 Patient Primary Population Objective Adult patients with Acute
Slide 85: NTZ Clinical Stage Program in ACLF
NTZ Clinical Stage Program in ACLF NTZ (Nitazoxanide) is a repositioned molecule
Slide 86: NTZ Impacts Multiple Pathways
NTZ NTZ Impacts Multiple Pathways NTZ antibacterial activity through inhibition of PFOR NTZ anti-inflammatory activity at least through NF-kB/MAPK pathway 86
Slide 87: Activity in Disease Models Support ACLF Clinical Development
NTZ Activity in Disease Models Support ACLF Clinical Development Reduces LPS-induced Beneficial effects on liver Alleviates liver and renal Reduces brain edema, Improves survival in inflammation in function markers (bil, alb) in damages in a model of inflammation markers and reverses treatment model
Slide 88: Completed Ph1 studies in hepatic and renal impairment
Completed Ph1 studies in subjects with NTZ hepatic impairment (HI) and renal impairment (RI) An Open-label, Phase 1, Multiple-dose Study to Evaluate the Pharmacokinetics and Safety of NTZ 500 mg twice daily for 7 days in Adult Subjects with Moderate & Severe Hepatic Impairment and Adult Healthy Cont
Slide 89: Development of a New Formulation, Proof-of-concept
Development of a New Formulation, Proof-of-concept, NTZ Study initiation targeted for 1H25 and Clinical data readout for 2H25 New formulation under development To permit greater dosing flexibility and ultimately better serve the ACLF patients: ▪ This population is known to have impaired/organs failu
Slide 90: SRT-015 Preclinical stage program in ACLF
SRT-015 Preclinical stage program in ACLF SRT-015 has been in-licensed from Seal Rock Therapeutics
Slide 91: An Injectable Formulation of ASK1 Inhibitor
SRT-015 An Injectable Formulation of ASK1 Inhibitor SRT-015 in brief ASK1 inhibitor in-licensed from Seal Rock Therapeutics in acute liver diseases Injectable formulation Targets inhibition of cellular apoptosis, inflammation and fibrosis Scientific rationale ASK1 inhibition has shown several potent
Slide 92: Target Engagement, MoA, Activity and Data Supporting Development in ACLF
SRT-015 Target Engagement, MoA, Activity and Data Supporting Development in ACLF Inhibits: -ASK-1 -phosphorylation of p38 -phosphorylation of JNK Activity: -Anti-inflammatory -Anti-apoptotic -Anti-fibrotic SRT-015 alleviates hepatic injury in a model of drug-induced liver injury, SRT-015 alleviates
Slide 93: Clinical Data Support Development in Liver Diseases
SRT-015 Clinical Data Support Development in Liver Diseases Multi-organ benefits of ASK1 modulation have been observed in several animal models and clinical trials1 › SRT-015 has demonstrated efficacy in multiple In kidney diseases preclinical models2 of acute and chronic liver => limits renal infla
Slide 94: CLM-022 Preclinical stage program in ACLF
CLM-022 Preclinical stage program in ACLF CLM-022 has been in-licensed from Celloram Inc.
Slide 95: Supporting Evidence and Next Steps
CLM-022 Supporting Evidence and Next Steps Preclinical CLM-022 • Blocks NLRP3 inflammasome activated by ATP and Nigericin • Blocks the endotoxin-induced production of inflammatory cytokines in an LPS sepsis model • Blocks ASC speck formation at nanomolar concentrations Preclinical NLRP3 • Decreases
Slide 96: VS-02-HE Preclinical program in ACLF
VS-02-HE Preclinical program in ACLF and its complications
Slide 97: Supporting Evidence and Next Steps
VS-02-HE Supporting Evidence and Next Steps About HE VS-02 in Preclinical data ACLF-HE • Superior urease inhibitory activity in vitro - Major complications of • Cytotoxicity and mutagenicity assessment (Ames test) IND enabling advanced liver disease and portal hypertension6 • Reduces plasmatic ammon
Slide 98: ACLF market opportunity
Towards a new GENFIT ACLF disease state GENFIT’s approach to ACLF ACLF market opportunity IQVIA Highlights on newsflow
Slide 99: Disclaimer
Disclaimer • IQVIA is not an “authorized person” for the purposes of the Financial Services and Markets Act 2000 (“FSMA”) and does not provide investment advice or carry on any other regulated activity under Part II of the FSMA 2000 (Regulated Activities) Order 2001. • Projections and related inform
Slide 100: Secondary market research to assess commercial opportunity in ACLF
We conducted secondary market research / literature review to assess the commercial opportunity in ACLF SCOPE ACLF disease landscape ACLF addressable market estimation • Performed a literature review and secondary market • Overall ACLF market size estimated based on research to understand: epidemiol
Slide 101: ACLF is a life-threatening disease involving multiple organ failure
ACLF is a life-threatening disease involving multiple organs failure and characterized by short term mortality Acute on chronic liver Life-threating disease characterized by acute decompensation of chronic liver disease associated with multiple organ failures failure and high short-term mortality1 5
Slide 102: Economic burden of ACLF on healthcare systems
Management of ACLF results in significant economic burden on healthcare systems, leading to a high need for innovative therapies The burden of ACLF in numbers 52 000 $ 16 days 6.4 Bn $ Average cost per Average length of hospital Estimated annual cost hospitalization per patient in stay1 burden in US
Slide 103: ACLF low prevalence and orphan designation eligibility
ACLF has low epidemiology and could be eligible to orphan designation; aging population and launch of targeted Tx can increase diagnosis rate Estimated current prevalence (1:100,000) Overview and future outlook 100 • In 2021, the prevalence of ACLF is 90 estimated to be ~294K across the US, EU4 80 a
Slide 104: Analogues selected to estimate price range
Several analogues were selected to estimate price range of upside potential, including one-off therapies for chronic disease and drugs for acute episodes Analogues considered • To identify relevant price range for Analogue MoA Features List Price (US) the ACLF drugs, different analogues Recombinant
Slide 105: Grade 1-2 ACLF potential ~4 bn USD addressable market
Overall, grade 1-2 ACLF may represent a potential ~4 bn USD addressable market opportunity in the US and EU4+UK by 2030 Ballpark overall market size by 2030, bn USD1 Assumptions / considerations 4.0 • Prevalence: 150K (EU4 + UK) / 90k (US) for grade 1-2 ACLF patients2 • Drug price could amount to $3
Slide 106: Detailed assumptions for addressable market in 2030
Detailed overview of assumptions used to estimate addressable market in 2030 in US & EU4+UK Assumptions / considerations Input Base Upside Rationale / Sources ~100K • US: Hernaez, et al., J of Hepatol (2019) Prevalence ~190 • EU4+UK: Moreau, R., et al., (2013) Table 10; ACLF 1 prevalence 45% 45% • I
Slide 107: ACLF is an attractive market opportunity with upside potential
ACLF is an attractive market opportunity with upside potential given significant unmet need for urgent treatment and easier clinical development Possibility to lead ACLF market growth with therapies being launched at a price fully representing their value ACLF is an attractive opportunity for Biotec
Slide 108: Highlights on newsflow
Towards a new GENFIT ACLF disease state GENFIT’s approach to ACLF ACLF market opportunity Highlights on newsflow
Slide 109: Highlights on newsflow
Highlights on newsflow Iqirvo® (Elafibranor1) Approval U.S. FDA June 10, 2024 Expected commercialization by Approval EMA September 19, 2024 partner Ipsen Approval CHMRA UK October 8, 2024 2024 2025 CLM-022 Preclinical Proof of Concept VS-01 Phase 2 UNVEIL-IT ® VS-01 Proof of Concept NTZ Proof of Con
Slide 110: Thank you
THANK YOU